We share a segment from the public radio show The Takeaway featuring Dan Gorenstein talking about 988.
Ryan Levi
Ryan is the managing editor for Tradeoffs, helping lead the newsroom’s editorial strategy and guide its coverage on its flagship podcast, digital articles, newsletters and live events. Ryan spent six years as a reporter and producer for Tradeoffs covering Medicaid, mental health, addiction and health technology, including artificial intelligence. Ryan’s work has won numerous national awards and been featured on NPR, PBS NewsHour and The Marshall Project. Ryan lives in Washington D.C.
Good Intentions Gone Awry
Why has a little-known program designed to help hospitals and clinics that serve low-income people become so controversial?
What Research Says About a Post-Roe World
The leader of a landmark abortion study shares what research and her own family experience suggest will happen to people who are denied abortions.
Four Studies to Help You Make Sense of a Post-Roe World
This week our Research Council shares studies to help make sense of a Post-Roe world.
Pain, Fear and Waste: The Costs of Unnecessary Care
We explore cascades of care — how a clinician’s desire to be thorough can snowball into a harmful spiral of unnecessary care.
Answering the Call, Part 2: Struggling to Staff the Nation’s New Crisis Line
In Part 2 of our 988 series, the scramble to staff the new mental health crisis line and the lessons 988 can learn from 911.
Fixing the Obamacare ‘Glitch’ That Pushed One Couple to Divorce
The Biden administration is trying to close a gap in the Affordable Care Act that blocks 5 million people from getting affordable health care.
How One Doctor Is Prepping for a World Without Roe
We talk with a Michigan OB-GYN determined to make sure her hospital is ready if abortion becomes illegal in her state.
Too Healthy for the Hospital, Too Sick for the Streets
Medical respite — a decades-old way of caring for homeless people — is on the rise.
How One Alzheimer’s Drug Is Changing the U.S. Drug Approval Conversation
Taking stock of the impact of the Aduhelm saga and Medicare’s decision to restrict coverage of the controversial treatment.
